Upstream Bio, Inc. 8-K

What Happened

• On March 26, 2026, Upstream Bio, Inc. announced its financial results and business highlights for the quarter and year ended December 31, 2025. The company furnished a press release containing those results as Exhibit 99.1 to the Form 8-K. The report was signed by CEO E. Rand Sutherland, M.D.

Key Details

• Filing date: March 26, 2026 (Current Report on Form 8-K).
• Period covered: Quarter and fiscal year ended December 31, 2025.
• Exhibit: Press release with results and business highlights furnished as Exhibit 99.1.
• Signature: Report signed by E. Rand Sutherland, M.D., Chief Executive Officer.

Why It Matters

• Earnings and year‑end results are material for investors because they contain revenue, operating results, and business milestones that can affect valuation and near‑term stock performance.
• The Form 8‑K furnishes the press release but does not itself include detailed financial statements beyond that release; investors should review the Exhibit 99.1 press release (and any accompanying SEC filings) for full figures and management commentary.
• Monitoring this release helps retail investors evaluate recent company performance, progress on corporate milestones, and any implications for future guidance or financing needs.